KOOL vs. THMO, LUMO, GDTC, BIOR, PYPD, XGN, IINN, CPIX, LSTA, and NEPH
Should you be buying Cesca Therapeutics stock or one of its competitors? The main competitors of Cesca Therapeutics include ThermoGenesis (THMO), Lumos Pharma (LUMO), CytoMed Therapeutics (GDTC), Biora Therapeutics (BIOR), PolyPid (PYPD), Exagen (XGN), Inspira Technologies Oxy B.H.N. (IINN), Cumberland Pharmaceuticals (CPIX), Lisata Therapeutics (LSTA), and Nephros (NEPH). These companies are all part of the "medical" sector.
ThermoGenesis (NASDAQ:THMO) and Cesca Therapeutics (NASDAQ:KOOL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, community ranking, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.
ThermoGenesis presently has a consensus price target of $5.00, indicating a potential upside of 620.46%. Given Cesca Therapeutics' higher possible upside, research analysts plainly believe ThermoGenesis is more favorable than Cesca Therapeutics.
ThermoGenesis has higher earnings, but lower revenue than Cesca Therapeutics.
Cesca Therapeutics has a net margin of -98.84% compared to Cesca Therapeutics' net margin of -190.31%. ThermoGenesis' return on equity of -77.30% beat Cesca Therapeutics' return on equity.
Cesca Therapeutics received 241 more outperform votes than ThermoGenesis when rated by MarketBeat users. Likewise, 70.45% of users gave Cesca Therapeutics an outperform vote while only 60.47% of users gave ThermoGenesis an outperform vote.
ThermoGenesis has a beta of 2.39, indicating that its share price is 139% more volatile than the S&P 500. Comparatively, Cesca Therapeutics has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500.
5.8% of ThermoGenesis shares are owned by institutional investors. Comparatively, 3.1% of Cesca Therapeutics shares are owned by institutional investors. 78.0% of ThermoGenesis shares are owned by company insiders. Comparatively, 68.9% of Cesca Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Cesca Therapeutics' average media sentiment score of 0.00 equaled ThermoGenesis'average media sentiment score.
Summary
Cesca Therapeutics beats ThermoGenesis on 7 of the 13 factors compared between the two stocks.
Get Cesca Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KOOL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KOOL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cesca Therapeutics Competitors List
Related Companies and Tools
